Accepted Manuscript

Identification of Novel B-Raf^{V600E} Inhibitors Employing FBDD Strategy

Peng-Fei Wang, Han-Yue Qiu, Ze-Feng Wang, Yong-Jiao Zhang, Zhong-Chang Wang, Dong-Dong Li, Hai-Liang Zhu

PII: S0006-2952(17)30114-4

DOI: http://dx.doi.org/10.1016/j.bcp.2017.02.022

Reference: BCP 12753

To appear in: Biochemical Pharmacology

Received Date: 11 December 2016 Accepted Date: 28 February 2017



Please cite this article as: P-F. Wang, H-Y. Qiu, Z-F. Wang, Y-J. Zhang, Z-C. Wang, D-D. Li, H-L. Zhu, Identification of Novel B-Raf^{V600E} Inhibitors Employing FBDD Strategy, *Biochemical Pharmacology* (2017), doi: http://dx.doi.org/10.1016/j.bcp.2017.02.022

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Identification of Novel B-Raf^{V600E} Inhibitors Employing FBDD Strategy

Peng-Fei Wang^{a†}, Han-Yue Qiu^{a†}, Ze-Feng Wang^a, Yong-Jiao Zhang^a, Zhong-Chang Wang^{a*}, Dong-Dong Li^{a, b*}, Hai-Liang Zhu^{a*}

^aState Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, People's Republic of China

^bCollege of Chemical Engineering, Nanjing Forestry University, Nanjing 210073, People's Republic of China

*Corresponding author. Tel. & fax: +86-25-83592672; e-mail: zhuhl@nju.edu.cn †These two authors contributed equally to this paper.

Abstract

B-Raf kinase is the key point in a main branch of mitogen-activated protein kinase pathways and some of its mutations, such as the V600E mutation, lead to the persistent activation of ERK signaling and the trigger of severe diseases, including melanoma and other somatic cancers. Several potent drugs have been approved to treat B-Raf-related tumors, however, cases of resistance and relapse have been reported universally. Hence, differential scaffolds are in need to alleviate the scarcity

Download English Version:

https://daneshyari.com/en/article/5552191

Download Persian Version:

https://daneshyari.com/article/5552191

<u>Daneshyari.com</u>